Amgen Inc.

AMGN · Healthcare · · USD

362.79 USD

0.00 (-0.23%)

● Updated 2026-07-10 18:08 Saudi Time ↻ Refresh

Short-term Mid-term Long-term

Fahodi Score BUY Mid-term (Position)

/ 100

Technical 100

Trend & RS 82

Momentum 62

Fundamental 54

Macro 65

Liquidity 43

Component	Score	Weight
Technical	100.0	20%
Trend & RS	82.3	30%
Momentum	61.7	15%
Fundamental	54.2	10%
Macro	65.2	20%
Liquidity	42.9	5%

Trade Setup

Entry	363.07
Stop Loss	346.13 (4.7%)
Target 1 (1:1)	380.01 (+4.7%)
Target 2 (2:1)	396.95 (+9.3%)

ATR(14)	8.47 (2.3%)
Risk per Share	16.94
Reward:Risk	2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor	Score	Z
Value	37.0	-0.52
Momentum	61.7	+0.47
Quality	61.2	+0.45
Composite	53.3

Quality Scores

Piotroski F-Score 5 /9 — Average

✓ ✓ ✗ ✗ ✗ ✗ ✓ ✓ ✓

1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover

Altman Z-Score 2.64 — Grey Zone

Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Overvalued

Metric	Stock	Sector	vs Peers
P/E Ratio	25.3	22.0	+15% above
P/B Ratio	21.3	4.0	Above
Dividend Yield	2.8%	1.5%	Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value

208.66

Market Price

362.79

Upside

-42.5%

Margin of Safety	-73.9%
Stage 1 PV (5yr FCF)	28,375,044,092
Terminal Value PV	84,238,351,729
Total Enterprise Value	112,613,395,821

Assumptions

Base FCF	6,200,168,652
Growth Rate (5yr)	5.8%
Terminal Growth	2.5%
Discount Rate (WACC)	9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.8%

Recommended Size

48.4%

Full Kelly

24.2%

Half Kelly

5.0%

Max Cap (Moderate)

Kelly inputs derived from quant score 74/100. Estimated win rate 62%, avg win 9.5%, avg loss 3.5%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary STRONG BUY

Bullish Signals

Bearish Signals

58.31

RSI(14)

6.6946

MACD

Relative Strength (RS) NEUTRAL

/ 99

RS Rating

✓ O'Neil PASS (≥80)

RS vs SPY	→ FLAT (-8.0% vs SPY 3M)
RS vs Sector	INLINE (Healthcare)
RS New High	No (62d since high)
Sector Outperformance	-2.5% (3M)

RS Line — stock / SPY (90 bars)

← older newer →

RS vs SPY 50-day SMA of RS

NEUTRAL: In line with the market — no strong outperformance or underperformance.

Technical Indicators

Indicator	Value	Signal
Rsi	58.31	NEUTRAL
Macd	6.6946	BULLISH
Ma Cross	343.01 / 333.93	GOLDEN CROSS
Trend Short		ABOVE SMA50
Trend Long		ABOVE SMA200
Bollinger		MIDDLE
Volume	0.11x	LOW

Key Levels

Level	Price
52-Week High	391.29
Bollinger Upper	375.94
SMA(200)	333.93
SMA(50)	343.01
SMA(20)	356.43
Current Price	362.79
Bollinger Lower	336.91
52-Week Low	269.77
ATR(14)	8.47

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

Insufficient data for Wyckoff analysis.

Volume Spread Analysis (last 5 bars)

Date	Signal	Vol	Description
2026-07-06	Normal	0.98x	Normal bar — no special VSA pattern
2026-07-07	Normal	0.68x	Normal bar — no special VSA pattern
2026-07-08	Normal	0.6x	Normal bar — no special VSA pattern
2026-07-09	Normal	0.59x	Normal bar — no special VSA pattern
2026-07-10	Normal	0.11x	Normal bar — no special VSA pattern

Ichimoku Cloud BULLISH

Line	Value	Status
Tenkan-sen (9)	366.06	Above Kijun
Kijun-sen (26)	350.62	Base line
Senkou A	358.34	Leading span A
Senkou B	346.68	Leading span B
Cloud	346.68 – 358.34	Bullish (Green)
Price vs Cloud	363.07	Above Cloud
Chikou Span	338.22	Bullish
Alignment Score	4/4	BULLISH